The role of inflammatory cytokines and NF-κB/MAPK signaling pathways in the evolution of familial Mediterranean fever: Current clinical perspectives and potential therapeutic approaches

Cellular Immunology

Volumn 260, Issue 1, 2009, Pages 6-13

  Haddad, John J ^a,b  

^a AMERICAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Lebanon)

^b UNIVERSITY OF BALAMAND   (Lebanon)

Author keywords

Cytokines; Familial Mediterranean fever; Inflammation; MAPK; NF B

Indexed keywords

C REACTIVE PROTEIN; COLCHICINE; FIBRINOGEN; HAPTOGLOBIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; PYRIN; REGULATOR PROTEIN; SERUM AMYLOID A; SERUM AMYLOID A1; TATA BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALBUMINURIA; AMYLOIDOSIS; APOPTOSIS; ARTHRALGIA; ARTHRITIS; AUTOSOMAL RECESSIVE INHERITANCE; CHROMOSOME 16P; ERYTHROCYTE SEDIMENTATION RATE; FAMILIAL MEDITERRANEAN FEVER; GENE MUTATION; GENETIC SCREENING; HUMAN; LEUKOCYTOSIS; MYALGIA; PERITONITIS; PLEURISY; POLYSEROSITIS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

CYTOKINES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FAMILIAL MEDITERRANEAN FEVER; HUMANS; INFLAMMATION; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 70350622696     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2009.08.003     Document Type: Review

References (72)

1. Marek-Yagel D., Berkun Y., Padeh S., et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum. 60 (2009) 1862-1866
2. Guz G., Kanbay M., and Ozturk M.A. Current perspectives on familial Mediterranean fever. Curr. Opin. Infect. Dis. 22 (2009) 309-315
3. De Socio G., Cerquaglia C., Curigliano V., et al. Association between familial Mediterranean fever a d retroperitoneal fibrosis: retroperitoneal fibrosis regression after colchicine therapy. Int. J. Immunopathol. Pharmacol. 22 (2009) 521-524
4. Fisher P.W., Ho L.T., Goldschmidt R., et al. Familial Mediterranean fever, inflammation and nephrotic syndrome: fibrillary glomerulopathy and the M680I missense mutation. BMC Nephrol. 4 (2003) 6
5. Ozen S., Aktay N., Lainka E., et al. Disease severity in children and adolescents with familial Mediterranean fever: a comparative study to explore environmental effects on a monogenic disease. Ann. Rheum. Dis. 68 (2009) 246-248
6. Mikula M., Buller A., Sun W., and Strom C.M. Prevalence of known mutations in the familial Mediterranean fever gene (MEFV) in various carrier screening populations. Genet. Med. 10 (2008) 349-352
7. Sarkisian T., Ajrapetian H., Beglarian A., Shahsuvarian G., and Egiazarian A. Familial Mediterranean fever in Armenian population. Georgian Med. News 156 (2008) 105-111
8. Duşunsel R., Dursun I., Gündüz Z., et al. Genotype-phenotype correlation in children with familial Mediterranean fever in a Turkish population. Pediatr. Int. 50 (2008) 208-212
9. Booty M.G., Chae J.J., Masters S.L., et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit?. Arthritis Rheum. 60 (2009) 1851-1861
10. James L.C., Keeble A.H., Khan Z., Rhodes D.A., and Trowsdale J. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function. Proc. Natl. Acad. Sci. USA 104 (2007) 6200-6205
11. Manna R., Cerquaglia C., Curigliano V., et al. Clinical features of familial Mediterranean fever: an Italian overview. Eur. Rev. Med. Pharmacol. Sci. 13 Suppl. 1 (2009) 51-53
12. Aksentijevich I., Torosyan E., Samuels J., et al. Mutation and haplotype studies of FMF reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. Am. J. Hum. Genet. 42 (1999) 949-962
13. Waite A.L., Schaner P., Hu C., et al. Pyrin and ASC co-localize to cellular sites that are rich in polymerizing actin. Exp. Biol. Med. (Maywood) 234 (2009) 40-52
14. Mansfield E., Chae J.J., Komarow H.D., et al. The familial Mediterranean fever protein, pyrin, associates with microtubules and colocalizes with actin filaments. Blood 98 (2001) 851-859
15. H. Akin, H. Onay, E. Turker, O. Cogulu, F. Ozkinay, MEFV mutations in patients with familial Mediterranean fever from the Aegean region of Turkey, Mol. Biol. Rep., in press, doi:10.1007/s11033-009-9543-1.
16. Kirkpantur A., Baydar D.E., Altun B., et al. Concomitant amyloidosis, renal papillary carcinoma and ipsilateral pelvicalyceal urothelial carcinoma in a patient with familial Mediterranean fever. Amyloid 16 (2009) 54-59
17. Sahin F.I., Yilmaz Z., Yurtcu E., and Baskin E. Comparison of the results of PCR-RFLP and reverse hybridization methods used in molecular diagnosis of FMF. Genet. Test. 12 (2008) 171-174
18. Sabbagh A.S., Ghasham M., Abdel Khalek R., et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean fever work-up: experience of a major tertiary care center. Mol. Biol. Rep. 35 (2008) 447-451
19. Mavragani C.P., Yiannakouris N., Zintzaras E., et al. Analysis of SAA1 gene polymorphisms in the Greek population: rheumatoid arthritis and FMF patients relative to normal controls. Homogeneous distribution and low incidence of AA amyloidosis. Amyloid 14 (2007) 271-275
20. Kelkitli E., Bilgici B., Tokgöz B., et al. SAA1 alpha/alpha alleles in amyloidosis. J. Nephrol. 19 (2006) 189-191
21. Lokuta M.A., Cooper K.M., Aksentijevich I., Kastner D.L., and Huttenlocher A. Neutrophil chemotaxis in a patient with neonatal-onset multisystem inflammatory disease and Muckle-Wells syndrome. Ann. Allergy Asthma Immunol. 95 (2005) 394-399
22. Tsuchiya-Suzuki A., Yazaki M., Nakamura A., et al. Clinical and genetic features of familial Mediterranean fever in Japan. J. Rheumatol. 36 (2009) 1671-1676
23. Bakkaloglu A., Duzova A., Ozen S., et al. Influence of serum amyloid A (SAA1) and SAA2 gene polymorphisms on renal amyloidosis, and on SAA/C-reactive protein values in patients with familial Mediterranean fever in the Turkish population. J. Rheumatol. 31 (2004) 1139-1142
24. Ray A., Shakya A., Kumar D., Benson M.D., and Ray B.K. Inflammation-responsive transcription factor SAF-1 activity is linked to the development of amyloid A amyloidosis. J. Immunol. 177 (2006) 2601-2609
25. Delibaş A., Oner A., Balci B., et al. Genetic risk factors of amyloidogenesis in familial Mediterranean fever. Am. J. Nephrol. 25 (2005) 434-440
26. Ozen S. Changing concepts in familial Mediterranean fever: is it possible to have an autosomal-recessive disease with only one mutation?. Arthritis Rheum. 60 (2009) 1575-1577
27. Fonnesu C., Cerquaglia C., Giovinale M., et al. Familial Mediterranean fever: a review for clinical management. Joint Bone Spine 76 (2009) 227-233
28. Ozçakar Z.B., Yalçinkaya F., Yüksel S., et al. Possible effect of subclinical inflammation on daily life in familial Mediterranean fever. Clin. Rheumatol. 25 (2006) 149-152
29. Makay B., Türkyilmaz Z., and Unsal E. Mean platelet volume in children with familial Mediterranean fever. Clin. Rheumatol. 28 (2009) 975-978
30. Colak B., Gurlek B., Yegin Z.A., et al. The relationship between the MEFV genotype, clinical features, and cytokine-inflammatory activities in patients with familial Mediterranean fever. Ren. Fail. 30 (2008) 187-191
31. Korkmaz C., Ozdogan H., Kasapçopur O., and Yazici H. Acute phase response in familial Mediterranean fever. Ann. Rheum. Dis. 61 (2002) 79-81
32. Haddad J.J., Olver R.E., and Land S.C. Antioxidant/pro-oxidant equilibrium regulates HIF-1α and NF-κB redox sensitivity. Evidence for inhibition by glutathione oxidation in alveolar epithelial cells. J. Biol. Chem. 275 (2000) 21130-21139
33. Haddad J.J. On the enigma of pain and hyperalgesia: a molecular perspective. Biochem. Biophys. Res. Commun. 353 (2007) 217-224
34. 193-195 receptor antagonism in the alveolar epithelium. Biochem. J. 355 (2001) 29-38
35. Haddad J.J., Safieh-Garabedian B., Saadé N.E., and Lauterbach R. Inhibition of glutathione-related enzymes augments LPS-mediated cytokine biosynthesis: involvement of an IκB/NF-κB-sensitive pathway in the alveolar epithelium. Int. Immunopharmacol. 2 (2002) 1567-1583
36. Haddad J.J., Land S.C., Tarnow-Mordi W.O., et al. Immunopharmacological potential of selective phosphodiesterase inhibition. II. Evidence for the involvement of an inhibitory-κB/nuclear factor-κB-sensitive pathway in alveolar epithelial cells. J. Pharmacol. Exp. Ther. 300 (2002) 567-576
37. Chae J.J., Wood G., Richard K., et al. The familial Mediterranean fever protein, pyrin, is cleaved by caspase-1 and activates NF-κB through its N-terminal fragment. Blood 112 (2008) 1794-1803
38. Masumoto J., Dowds T.A., Schaner P., et al. ASC is an activating adaptor for NF-κB and caspase-8-dependent apoptosis. Biochem. Biophys. Res. Commun. 303 (2003) 69-73
39. Nedjai B., Hitman G.A., Yousaf N., et al. Abnormal tumor necrosis factor receptor I cell surface expression and NF-κB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 58 (2008) 273-283
40. Churchman S.M., Church L.D., Savic S., et al. A novel TNFRSF1A splice mutation associated with increased nuclear factor κB (NF-κB) transcription factor activation in patients with tumor necrosis factor receptor associated periodic syndrome (TRAPS). Ann. Rheum. Dis. 67 (2008) 1589-1595
41. Papin S., Cazeneuve C., Duquesnoy P., et al. The tumor necrosis factor α-dependent activation of the human Mediterranean fever (MEFV) promoter is mediated by a synergistic interaction between C/EBP β and NF κB p65. J. Biol. Chem. 278 (2003) 48839-48847
42. Yousaf N., Gould D.J., Aganna E., et al. Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-κB activation. Arthritis Rheum. 52 (2005) 2906-2916
43. p38-dependent regulation of pro-inflammatory cytokine production. Biochem. Pharmacol. 63 (2002) 305-320
44. Haddad J.J. Mitogen-activated protein kinases and the evolution of Alzheimer's: a revolutionary neurogenetic axis for therapeutic intervention?. Prog. Neurobiol. 73 (2004) 359-377
45. Haddad J.J., and Land S.C. Redox/ROS regulation of lipopolysaccharide-induced mitogen-activated protein kinase (MAPK) activation and MAPK-mediated TNF-α biosynthesis. Br. J. Pharmacol. 135 (2002) 520-536
46. Cano E., and Mahadevan L.C. Parallel signal processing among mammalian MAPKs. Trends Biochem. Sci. 20 (1995) 117-122
47. Enslen H., and Davis R.J. Regulation of MAP kinases by docking domains. Biol. Cell 93 (2001) 5-14
48. Raingeaud J., Gupta S., Rogers J.S., et al. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J. Biol. Chem. 270 (1995) 7420-7426
49. Robinson M.J., and Cobb M.H. Mitogen-activated protein kinase pathways. Curr. Opin. Cell Biol. 9 (1997) 180-186
50. Han J., Lee J.D., Bibbs L., and Ulevitch R.J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265 (1994) 808-811
51. Dinarello C.A. Interleukin-1β and the autoinflammatory diseases. N. Engl. J. Med. 360 (2009) 2467-2470
52. Livneh A., Langevitz P., Zemer D., et al. Criteria for the diagnosis of FMF. Arthritis Rheum. 40 (1997) 1879-1885
53. Schaner P.E., and Gumucio D.L. Familial Mediterranean fever in the post-genomic era: how an ancient disease is providing new insights into inflammatory pathways. Curr. Drug Targets Inflamm. Allergy 4 (2005) 67-76
54. Sit M.T., and Arroyo R. Common rheumatic diseases of the Middle East. Mil. Med. 174 (2009) 311-314
55. Balci-Peynircioǧlu B., Taşkiran Z.E., Türel B., et al. The analysis of interleukin-1 receptor antagonist and interleukin-1beta gene polymorphisms in Turkish FMF patients: do they predispose to secondary amyloidosis?. Clin. Exp. Rheumatol. 26 (2008) S99-S102
56. Seshadri S., Duncan M.D., Hart J.M., Gavrilin M.A., and Wewers M.D. Pyrin levels in human monocytes and monocyte-derived macrophages regulate IL-1β processing and release. J. Immunol. 179 (2007) 1274-1281
57. Papin S., Cuenin S., Agostini L., et al. The SPRY domain of Pyrin, mutated in familial Mediterranean fever patients, interacts with inflammasome components and inhibits proIL-1β processing. Cell Death Differ. 14 (2007) 1457-1466
58. Baykal Y., Saglam K., Yilmaz M.I., et al. Serum sIL-2r, IL-6, IL-10 and TNF-alpha level in familial Mediterranean fever patients. Clin. Rheumatol. 22 (2003) 99-101
59. Erken E., Güneşaçar R., Ozbek S., and Konca K. Serum soluble interleukin-2 receptor levels in familial Mediterranean fever. Ann. Rheum. Dis. 55 (1996) 852-855
60. Centola M., Wood G., Frucht D.M., et al. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 95 (2000) 3223-3231
61. Aypar E., Ozen S., Okur H., et al. Th1 polarization in familial Mediterranean fever. J. Rheumatol. 30 (2003) 2011-2013
62. Davtyan T.K., Hakopyan G.S., Avetisyan S.A., and Mkrtchyan N.R. Impaired endotoxin tolerance induction in patients with familial Mediterranean fever. Pathobiology 73 (2006) 26-39
63. Direskeneli H., Ozdogan H., Korkmaz C., Akoglu T., and Yazici H. Serum soluble intercellular adhesion molecule 1 and interleukin 8 levels in familial Mediterranean fever. J. Rheumatol. 29 (1999) 1983-1986
64. Mege J.L., Dilsen N., Sanguedolce V., et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL)-6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J. Rheumatol. 20 (1993) 1544-1549
65. Erken E., Ozer H.T., and Gunesacar R. Plasma interleukin-10 and interleukin-12 levels in patients with familial Mediterranean fever. Rheumatol. Int. 26 (2006) 862-864
66. Simsek I., Pay S., Pekel A., et al. Serum proinflammatory cytokines directing T helper 1 polarization in patients with familial Mediterranean fever. Rheumatol. Int. 27 (2007) 807-811
67. Musabak U., Sengul A., Oktenli C., et al. Does immune activation continue during an attack-free period in familial Mediterranean fever?. Clin. Exp. Immunol. 138 (2004) 526-533
68. Karahan Z.C., Ozturk A., Akar E., and Akar N. Interleukin-6 (IL-6) -174 G/C polymorphism in familial Mediterranean fever patients with and without amyloidosis. J. Nephrol. 18 (2005) 582-584
69. J. Trübenbach, G. Wildhardt, J. Niebel, H. Hawle, D. Steinberger, A monoallelic double mutation as a cause for TNF receptor-associated periodic fever syndrome, Rheumatol. Int., in press, doi:10.1007/s00296-009-0996-2.
70. Nedjai B., Hitman G.A., Quillinan N., et al. Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 60 (2009) 619-625
71. Jesus A.A., Oliveira J.B., Aksentijevich I., et al. TNF receptor-associated periodic syndrome (TRAPS): description of a novel TNFRSF1A mutation and response to etanercept. Eur. J. Pediatr. 167 (2008) 1421-1425
72. Sacré K., Brihaye B., Lidove O., et al. Dramatic improvement following interleukin 1β blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-α therapy. J. Rheumatol. 35 (2008) 357-358